The global rifaximin market size is calculated at USD 2.04 billion in 2025 and is forecasted to reach around USD 5.09 billion by 2034, accelerating at a CAGR of 10.72% from 2025 to 2034. The North America market size surpassed USD 736.00 million in 2024 and is expanding at a CAGR of 10.85% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Rifaximin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Rifaximin Market Revenue and Volume, by Indication
8.1.1 Irritable Bowel Syndrome (IBS-D) with Diarrhea
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Hepatic Encephalopathy (HE)
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Traveler’s Diarrhea
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast
9.1. Rifaximin Market Revenue and Volume, by Dosage Form
9.1.1. Tablets
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Oral Suspension
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast
10.1. Rifaximin Market Revenue and Volume, by Distribution Channel
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Indication
11.1.2. Market Revenue and Volume Forecast, by Dosage Form
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Indication
11.1.4.2. Market Revenue and Volume Forecast, by Dosage Form
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Indication
11.1.5.2. Market Revenue and Volume Forecast, by Dosage Form
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Indication
11.2.2. Market Revenue and Volume Forecast, by Dosage Form
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Indication
11.2.4.2. Market Revenue and Volume Forecast, by Dosage Form
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Indication
11.2.5.2. Market Revenue and Volume Forecast, by Dosage Form
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Indication
11.2.6.2. Market Revenue and Volume Forecast, by Dosage Form
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Indication
11.2.7.2. Market Revenue and Volume Forecast, by Dosage Form
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Indication
11.3.2. Market Revenue and Volume Forecast, by Dosage Form
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Indication
11.3.4.2. Market Revenue and Volume Forecast, by Dosage Form
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Indication
11.3.5.2. Market Revenue and Volume Forecast, by Dosage Form
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Indication
11.3.6.2. Market Revenue and Volume Forecast, by Dosage Form
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Indication
11.3.7.2. Market Revenue and Volume Forecast, by Dosage Form
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Indication
11.4.2. Market Revenue and Volume Forecast, by Dosage Form
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Indication
11.4.4.2. Market Revenue and Volume Forecast, by Dosage Form
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Indication
11.4.5.2. Market Revenue and Volume Forecast, by Dosage Form
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Indication
11.4.6.2. Market Revenue and Volume Forecast, by Dosage Form
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Indication
11.4.7.2. Market Revenue and Volume Forecast, by Dosage Form
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Indication
11.5.2. Market Revenue and Volume Forecast, by Dosage Form
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Indication
11.5.4.2. Market Revenue and Volume Forecast, by Dosage Form
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Indication
11.5.5.2. Market Revenue and Volume Forecast, by Dosage Form
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.1. Alfasigma S.p.A.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Glenmark Pharmaceuticals
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sanofi
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Lupin Limited
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Zydus Cadila
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Aurobindo Pharma Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hetero Drugs Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Amneal Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description